Skip to main content
OpenTrials

Clinical trial condition

Lymphatic Diseases

Explore clinical trials studying Lymphatic Diseases. Study availability and eligibility vary by location and protocol.

60 public trials 6 recruiting studies
Refine in advanced search Browse all conditions

Lymphatic Diseases trial results

Completed

DPX-Survivac and Checkpoint Inhibitor in DLBCL

NCT03349450

Conditions
Adult Diffuse Large Cell Lymphoma, Adult Refractory Diffuse Large B-Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, +18 more
Locations
  • Tom Baker Cancer Centre - Alberta Health Services Calgary, Alberta, Canada
  • Nova Scotia Health Authority: Queen Elizabeth II Health Sciences Centre Halifax, Nova Scotia, Canada
  • London Health Sciences Centre London, Ontario, Canada
  • Ottawa Hospital Research Institute Ottawa, Ontario, Canada
View Trial Details
Completed

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

NCT03744676

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Local Institution - 0057 Los Angeles, California, United States
  • Local Institution - 0060 Denver, Colorado, United States
  • Local Institution - 0089 Miami, Florida, United States
  • Local Institution - 0081 Orlando, Florida, United States
View all 23 locations
View Trial Details
Completed

Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)

NCT05529524

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Centre Hospitalier de La Cote Basque; Hematologie Bayonne, France
  • Hopital Claude Huriez; Hematologie Lille, France
  • Institut Paoli Calmettes Marseille, France
  • CHU Saint Eloi; Service d'Hématologie Clinique Montpellier, France
View Trial Details
Completed

Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)

NCT02658968

Conditions
AIDS-Related Complex, Blood-Borne Infections, Communicable Diseases, +29 more
Locations
  • University of California, San Diego (UCSD) - Moores Cancer Center San Diego, California, United States
  • University of California, San Francisco (UCSF) - Innovation, Technology & Alliances San Francisco, California, United States
  • Sylvester Comprehensive Cancer Centre Miami, Florida, United States
  • Klinikum rechts der Isar der TU München Munich, Germany
View Trial Details
Completed

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

NCT02733042

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +20 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Pinnacle Oncology Hematology Scottsdale, Arizona, United States
  • University of Colorado Cancer Center Aurora, Colorado, United States
  • Shands Cancer Center University of Florida Gainesville, Florida, United States
View all 66 locations
View Trial Details
Completed

Sildenafil for the Treatment of Lymphatic Malformations

NCT02335242

Conditions
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, +3 more
Locations
  • Stanford University Stanford, California, United States
  • University of Colorado, Denver Aurora, Colorado, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago Chicago, Illinois, United States
View Trial Details
Completed

A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

NCT01667133

Conditions
Bone Marrow Diseases, Chronic Disease, Chronic Myeloid Leukemia (CML), +16 more
Locations
  • Aichi Cancer Center Hospital Nagoya, Aichi-ken, Japan
  • Akita University Hospital Akita, Japan
  • Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital Hiroshima, Japan
  • Kyushu University Hospital Hukuoka-shi, Hukuoka, Japan
View Trial Details

Related conditions